A volunteer in Brazil for the clinical trials of COVID-19 vaccine being developed by Europe based pharmaceutical company AstraZeneca Plc. (LON: AZN) in collaboration with Oxford University has passed away.
Oxford confirmed the sad news further adding after a meticulous assessment no concerns about safety of the clinical trial the trials came up hence the trials will continue as scheduled.
Reliable sources revealed that if the volunteer had received the COVID-19 vaccine prior his/her death then the trials would have been suspended immediately, this means that the candidate had only received a meningitis jab.
The Federal University of Sao Paulo is assisting in carrying out phase 3 trials in Brazil. The University confirmed indeed the study participant was Brazilian but did not diverge into any further details concerning the person. An independent review committee from the University also recommended for the vaccine trials to go on as intended.
“Everything is proceeding as expected, without any record of serious vaccine-related complications involving any of the participating volunteers,” said the Federal university of Sao Paulo.
Citing the University thousands have already been recruited and from cities across Brazil and have already received the first dose.
“So far, 8,000 of the planned 10,000 volunteers in the trial have been recruited and given the first dose in six cities in Brazil, and many have already received the second shot,” added the University.